Range of suitable people: CDEC talked over the uncertainty in the number of individuals with moderately severe to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are categorised as acquiring delicate or moderate disease may have a intense bleeding